Huateng Pharma Completed Series B Round of Financing
Recently, Hunan Huateng Pharmaceutical Co., Ltd. (hereafter called Huateng Pharma) completed a series B financing of 117 million yuan. This round of financing was led by CITIC Securities, followed by Hunan Xingxiang Group, Shenzhen Hongfu No. 7, and Zhou Qilin, an academician of the Chinese Academy of Sciences. This round of financing will be mainly used for the research and development of PEGylated peptides and protein drugs, the development of new target class I new drugs, the development and industrial production of blockbuster generic drugs, and the production and construction of pharmaceutical preparation bases.
Huateng Pharma was established in 2013 and founded by Dr. Deng Zeping, a National High-level Talents Special Support Plan Expert, and an Expert of Hundred Talents Program of Hunan Province. Huateng Pharma is a high-tech enterprise dedicated to the research and development and production of high-end biomedical chemical products, as well as the research and development of precise targeted anti-tumor drugs.
CITIC Securities stated that leading investment in Huateng Pharma, in addition to the company’s strong technical strength and good development momentum, it is believed that Huateng Pharma is a team with a rich international vision and a strong sense of innovation, that is the same as other investors. "Huateng Pharma has seized the critical period of the rise of the domestic biopharmaceutical industry and is committed to driving the development of Hunan Province and even China's biopharmaceutical industry. As a high-tech enterprise, it has many high-tech talents and fully possesses the advantages of the right time and place." said the CITIC Securities. Like CITIC Securities, Zhou Qilin, an academician of the Chinese Academy of Sciences, is also one of the investors. Zhou Qilin, who has made outstanding achievements in organic chemistry in China hopes that Huateng Pharma should seize the strategic opportunity period and accelerate the company's high-quality development with a sense of urgency.
Huateng Pharma won the recognition of the capitalism market once again after being led by the Boyi Fund of Tasly in 2019. Our president Mr. Deng said, the successful completion of the two rounds of financing has injected strong impetus into our company's development, which will definitely help our company to go public quickly. It will also promote our company's high-speed development, and make outstanding contributions to the development of human medicine and health industry.